{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:50:23Z","timestamp":1782190223744,"version":"3.54.5"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is associated with an extremely poor prognosis, with long-term survival being exceedingly rare. Here, we follow-up on three long-term survivors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study initially included eight patients with PDAC who underwent radical resection via Whipple\u2019s procedure with no evidence of distant metastases. Two of these patients received allogeneic hematopoietic cell transplantation (HCT) in a previously published trial. The remaining six patients, who served as controls and did not receive HCT, died of progressive PDAC within one to four years. Additionally, a 60-year-old male with PDAC who underwent partial pancreatectomy and gastrectomy received HCT from a matched unrelated donor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patient 1 developed mild acute graft-versus-host disease (GVHD) of the skin, followed by chronic GVHD. He subsequently underwent surgery for oral cancer and remains alive 21 years after the initial PDAC diagnosis, with no evidence of recurrence. Patient 2 experienced severe acute gastrointestinal GVHD and recurrent chronic bronchiolitis obliterans. He died of esophageal cancer 19 years after PDAC diagnosis. Patient 3 experienced graft rejection and multiple medical complications, including radical surgery for colorectal cancer, yet remains cancer-free 15 years after PDAC diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In conclusion, HCT may confer anticancer effects in patients with radically resected PDAC. Further investigations are warranted to confirm its therapeutic value.<\/jats:p>\n                    <jats:p>\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      Identifier: NCT02207985\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1766025","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:34:01Z","timestamp":1782189241000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long term survival in three pancreatic cancer patients following Whipple\u2019s procedure and allogeneic hematopoietic cell transplantation"],"prefix":"10.3389","volume":"17","author":[{"given":"Olle","family":"Ringden","sequence":"first","affiliation":[{"name":"Translational Cell Therapy Research, Department of Clinical Science Intervention and Technology (CLINTEC), Karolinska institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"Translational Cell Therapy Research, Department of Clinical Science Intervention and Technology (CLINTEC), Karolinska institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"T\u00f6rlen","sequence":"additional","affiliation":[{"name":"Department of Cell Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska Comprehensive Cancer Center, Karolinska Advanced Therapy Medicinal Products (ATMP) Center, Karolinska University Hospital","place":["Stockholm, Sweden"]},{"name":"Therapeutic immunology and transfusion medicine, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[{"name":"Department of Cell Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska Comprehensive Cancer Center, Karolinska Advanced Therapy Medicinal Products (ATMP) Center, Karolinska University Hospital","place":["Stockholm, Sweden"]},{"name":"Department of Laboratory Medicine, Karolinska Institute","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Permert","sequence":"additional","affiliation":[{"name":"Department of Surgery, CLINTEC, Karolinska Institutet","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102655","article-title":"Recent insights into the biology of pancreatic cancer","volume":"53","author":"Yao","year":"2020","journal-title":"EBioMedicine"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006822","article-title":"Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma","volume":"12","author":"Amaria","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-85516-3_651","article-title":"Implementation of best practices in pancreatic cancer care in the Netherlands: A stepped-wedge randomized clinical trial","volume":"159","author":"Mackay","year":"2024","journal-title":"JAMA Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znaa146","article-title":"Effect of centralization and regionalization of pancreatic surgery on resection rates and survival","volume":"108","author":"Latenstein","year":"2021","journal-title":"Br J Surg"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000006208","article-title":"Centralization of pancreaticoduodenectomy: A systematic review and spline regression analysis to recommend minimum volume for a specialist pancreas service","volume":"279","author":"Kotecha","year":"2024","journal-title":"Ann Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30148-0","article-title":"Precision oncology for pancreatic cancer in real-world settings","volume":"21","author":"Kleeff","year":"2020","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008735","article-title":"Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy","volume":"12","author":"Betof Warner","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00394-1","article-title":"Pancreatic cancer: still a cold case","volume":"23","author":"Reni","year":"2022","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v49.4.511.511","article-title":"One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation","volume":"49","author":"Thomas","year":"1977","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3109\/10408368309165762","article-title":"Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation","volume":"304","author":"Weiden","year":"1981","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v75.3.555.bloodjournal753555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v88.4.1501.bloodjournal8841501","article-title":"Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer","volume":"88","author":"Eibl","year":"1996","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(05)65517-1","article-title":"Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia","volume":"348","author":"Ben-Yosef","year":"1996","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1999.17.7.2044","article-title":"Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect","volume":"17","author":"Childs","year":"1999","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702337","article-title":"Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia","volume":"25","author":"Zetterquist","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/sj.bmt.1703609","article-title":"Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients","volume":"30","author":"Bay","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703932","article-title":"Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation","volume":"31","author":"Omuro","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.5966\/sctm.2015-0291","article-title":"Concise review: Pancreatic cancer and bone marrow-derived stem cells","volume":"5","author":"Blogowski","year":"2016","journal-title":"Stem Cells Transl Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/bmt.2008.94","article-title":"Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey","volume":"42","author":"Kanda","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2009.07886.x","article-title":"The allogeneic graft-versus-cancer effect","volume":"147","author":"Ringden","year":"2009","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl086","article-title":"Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe","volume":"17","author":"Barkholt","year":"2006","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.11.036","article-title":"Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience","volume":"15","author":"Aglietta","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.12.017","article-title":"Long-term follow-up of allogeneic hematopoietic stem cell transplantation for solid cancer","volume":"22","author":"Omazic","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023660","article-title":"Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation","volume":"144","author":"Kean","year":"2024","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000164","article-title":"A preliminary report: Radical surgery and stem cell transplantation for the treatment of patients with pancreatic cancer","volume":"40","author":"Omazic","year":"2017","journal-title":"J Immunother"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V94.2.455","article-title":"Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation","volume":"94","author":"Ringden","year":"1999","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198603203141201","article-title":"Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia","volume":"314","author":"Storb","year":"1986","journal-title":"N Engl J Med"},{"key":"B30","article-title":"Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings","volume":"15","author":"Ringden","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0801","article-title":"Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care","volume":"100","author":"Svahn","year":"2002","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"crossref","first-page":"1384137","DOI":"10.3389\/fimmu.2024.1384137","article-title":"Better clinical outcomes and lower triggering of inflammatory cytokines for allogeneic hematopoietic cell transplant recipients treated in home care versus hospital isolation - the Karolinska experience","volume":"15","author":"Ringden","year":"2024","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3949","article-title":"Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma","volume":"102","author":"Rubio","year":"2003","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B36","article-title":"Patient and caregiver awareness of pancreatic cancer treatments and clinical trials","volume":"7","author":"Engebretson","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia","volume":"27","author":"Ringden","year":"2009","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1097\/01.TP.0000058515.02300.5E","article-title":"Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans","volume":"75","author":"Soderdahl","year":"2003","journal-title":"Transplantation"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/00006676-200404000-00027","article-title":"Nonmyeloablative allogeneic stem cell transplantation for patients with unresectable pancreatic cancer","volume":"28","author":"Takahashi","year":"2004","journal-title":"Pancreas"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.3109\/10428199609045715","article-title":"The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"24","author":"Ringden","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"B42","first-page":"79","article-title":"Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients","volume":"14","author":"Aschan","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01390.x","article-title":"GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants","volume":"84","author":"Olsson","year":"2010","journal-title":"Eur J Haematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic Malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08756.x","article-title":"Secondary cancers following allogeneic haematopoietic cell transplantation in adults","volume":"154","author":"Majhail","year":"2011","journal-title":"Br J Haematol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199405000-00001","article-title":"Secondary Malignancies after marrow transplantation for leukemia or aplastic anemia","volume":"57","author":"Witherspoon","year":"1994","journal-title":"Transplantation"},{"key":"B48","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2014.07.009","article-title":"Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning","volume":"20","author":"Ringden","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.12.041","article-title":"The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation","volume":"113","author":"Ringden","year":"2009","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.11.554","article-title":"Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings","volume":"30","author":"Ringden","year":"2016","journal-title":"Leukemia"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-05-1098","article-title":"High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients","volume":"65","author":"Schmitz-Winnenthal","year":"2005","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1041588","article-title":"Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation","volume":"173","author":"Knoll","year":"2005","journal-title":"CMAJ"},{"key":"B53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ctrv.2019.06.005","article-title":"Checkpoint inhibitors in pancreatic cancer","volume":"78","author":"Henriksen","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco.19.02105","article-title":"Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the Phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00590","article-title":"Randomized Phase III trial of Pegvorhyaluronidase Alfa with Nab-Paclitaxel plus Gemcitabine for patients with Hyaluronan-High metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/sla.0000000000004669","article-title":"A Phase 3 randomized clinical trial of chemotherapy with or without Algenpantucel-L (HyperAcute-Pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer","volume":"275","author":"Hewitt","year":"2022","journal-title":"Ann Surg"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02659","article-title":"Devimistat (CPI-613) with modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) versus FFX for patients with metastatic adenocarcinoma of the pancreas: The Phase III AVENGER 500 study","volume":"42","author":"Philip","year":"2024","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4274\/balkanmedj.galenos.2023.2022-10-56","article-title":"Risk of secondary Malignancies in hematopoietic stem cell transplantation recipients: A nationwide population-based study in Taiwan","volume":"40","author":"Liu","year":"2023","journal-title":"Balkan Med J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1766025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:34:06Z","timestamp":1782189246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1766025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2026.1766025"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1766025","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1766025"}}